Showing results (21-30 of 72) with videos related to
Sort By:
Pageof 8
European Journal of Cancer (Oxford, England : 1990)|June 17, 2014
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanomaRichard D Carvajal, Michael K Wong, John A Thompson, et al.Cancer Medicine|July 20, 2024
Health-related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trialKetty Peris, Timothy J Inocencio, Alexander J Stratigos, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2019
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant MelanomaAntoni Ribas, Adil Daud, Anna C Pavlick, et al.Journal of Surgical Oncology|October 12, 2019
A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision makingChloe Friedman, Madison Lyon, Robert J Torphy, et al.Investigational New Drugs|November 12, 2017
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanomaSandra P D'Angelo, Omid A Hamid, Ahmad Tarhini, et al.Annals of Surgical Oncology|September 19, 2021
Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node DissectionRobert J Torphy, Chloe Friedman, Felix Ho, et al.Investigational New Drugs|September 25, 2007
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanomaKarl D Lewis, William A Robinson, Michael J Millward, et al.Journal for Immunotherapy of Cancer|January 20, 2018
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trialHoward L Kaufman, Jeffery S Russell, Omid Hamid, et al.Nature Medicine|June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patientsRyan J Sullivan, Omid Hamid, Rene Gonzalez, et al.The Journal of Investigative Dermatology|May 25, 2012
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistanceYuchun Luo, Lixia Z Ellis, Katiuscia Dallaglio, et al.Pageof 8